Here are 1-3 brief analogies for the company:

• It's like a clinical-stage biotech company similar to an early Moderna, but with surprisingly diverse operations in appliance recycling and cellular technology.
• Think of it as a pharmaceutical firm aspiring to develop breakthrough pain treatments like Vertex Pharmaceuticals, yet also running a business akin to an appliance recycling service and a small cellular modem maker.

null

AI Financial (AIFC), which according to the provided background operates as JanOne Inc., serves a diverse customer base across its three segments: Biotechnology, Recycling, and Technology.

Given that two of its three segments (Recycling and Technology) primarily serve other businesses, and the Biotechnology segment also involves business-to-business partnerships for development and commercialization, the company primarily sells to other companies.

Its major customers fall into the following categories:

• Utilities: These companies engage AI Financial for turnkey appliance recycling and replacement services as part of their energy efficiency programs. The specific names of these utilities are not provided in the description.
• Sponsors of Energy Efficiency Programs: Alongside utilities, these organizations (which can include government entities, non-profits, or other corporations) contract AI Financial for its recycling and replacement services. Specific names are not provided.
• Technology Companies / Manufacturers: Customers for the cellular transceiver modules and associated wireless services provided by the Technology segment would typically be other companies involved in electronics manufacturing, IoT, or telecommunications. Specific names are not provided.
• Biotechnology and Pharmaceutical Companies: For the Biotechnology segment, AI Financial engages in identifying, acquiring, licensing, developing, partnering, and commercializing therapies. These activities imply business-to-business customers in the form of development partners, licensees, or distributors in the pharmaceutical and biotechnology industries. Specific names are not provided.

null

Tony Isaac

President, Chief Executive Officer

Tony Isaac was appointed CEO of AI Financial Corporation (formerly JanOne Inc. and ALT5 Sigma Corporation) in May 2015, holding the position for over 10 years. He has led the company through its evolution from a clinical-stage biopharmaceutical company (JanOne Inc.) to a fintech company providing blockchain-powered payment, trading, and settlement infrastructure (ALT5 Sigma Corporation), and now to AI Financial Corporation, which is focused on expanding into AI-driven financial infrastructure, payments, and tokenization.

Steven M. Plumb

Director of Finance/Chief Financial Officer

Steven M. Plumb was appointed Director of Finance/Chief Financial Officer of AI Financial Corporation on November 20, 2025.

Anthony Giordano

Chief Technology/Scientific/R&D Officer

Anthony Giordano has served as the Chief Technology/Scientific/R&D Officer since December 2, 2019.

William Inman

Corporate Officer/Principal

William Inman was appointed as a Corporate Officer/Principal on January 20, 2026.

Denis E. Grande

Secretary

Denis E. Grande holds the position of Secretary for AI Financial Corporation.

The public company AI Financial (symbol: AIFC) faces several key risks, primarily stemming from the diversified and early-stage nature of its business segments as described in the provided background.

1. Clinical Trial Failure and Regulatory Approval Risk for Lead Product Candidate. As a clinical-stage biopharmaceutical company, a primary risk is the potential failure of its lead product candidate, JAN101, in ongoing or future clinical trials. Even if trials are successful, there is a significant risk that JAN101 may not receive the necessary regulatory approvals (e.g., from the FDA) for commercialization. Such failures or delays could lead to substantial financial losses, hinder the company's ability to generate revenue from its biotechnology segment, and severely impact its overall valuation and future prospects.
2. Market Acceptance and Commercialization Challenges. Should JAN101 successfully navigate the clinical and regulatory pathways, the company would then face the considerable challenge of achieving market acceptance and successful commercialization. The market for non-opioid pain treatments and therapies for conditions like peripheral artery disease is competitive. Risks include potential difficulties in gaining physician adoption, securing favorable reimbursement policies, competition from existing or new treatments, and the ability to effectively market and distribute the product.
3. Execution Risk from Disparate Business Segments. The company operates across three distinct and seemingly unrelated segments: Biotechnology, Recycling, and Technology. This diversification presents significant execution risks, including challenges in strategic focus, efficient allocation of capital and management resources, and maintaining operational expertise across vastly different industries. The capital-intensive nature of pharmaceutical development may strain resources that could otherwise support the recycling and technology segments, potentially hindering overall company profitability and growth across its varied ventures.

null

Based on the information provided and recent public data, AI Financial Corporation (AIFC) is a fintech company that evolved from JanOne Inc., through a name change to ALT5 Sigma Corporation, and then to its current name, AI Financial Corporation. While the background describes JanOne Inc.'s operations across biotechnology, recycling, and technology segments, current information indicates AI Financial Corporation's primary focus is on fintech, digital assets, and related infrastructure. However, the biotech activities from its JanOne Inc. past, specifically the development of non-opioid pain therapies, are still noted in connection with the company's evolution. The recycling and cellular transceiver modules segments are not explicitly mentioned as current core businesses for AI Financial Corporation. The addressable markets for AI Financial (AIFC)'s main products and services are as follows: * Fintech, Blockchain-Powered Payment, Trading, Settlement Infrastructure for Digital Assets, and Tokenization: The global blockchain market was valued at approximately USD 11.85 billion in 2022 and is projected to reach around USD 469.49 billion by 2032, with a compound annual growth rate (CAGR) of 45.4% from 2023 to 2032. The global digital asset management market was valued at USD 5.06 billion in 2024 and is expected to reach USD 18.04 billion by 2029, growing at a CAGR of 29.02%. The tokenization market is a rapidly expanding area within the broader digital asset and blockchain space. * JAN101 (Biotechnology product targeting pain in Peripheral Artery Disease and Diabetic Neuropathy): * The global peripheral artery disease (PAD) treatment market was estimated at USD 7.3 billion in 2024 and is projected to reach USD 11.3 billion by 2033, growing at a CAGR of 5.2% from 2025 to 2033. North America held the largest share of 43.5% of the global market in 2024. The U.S. peripheral arterial disease treatment market was valued at USD 805.35 billion in 2024 and is projected to reach around USD 1,701.48 billion by 2034, growing at a CAGR of 7.77% from 2025 to 2034. The global neuropathic pain treatment market, which includes diabetic neuropathy, was valued at USD 8.2 billion in 2024 and is expected to grow to USD 18.1 billion by 2034, at a CAGR of 8.3% from 2025. The diabetic neuropathy segment generated USD 3 billion in revenue in 2024. The U.S. neuropathic pain treatment market was valued at USD 3.3 billion in 2024. * The global diabetic neuropathy treatment market size was estimated at USD 4.34 billion in 2023 and is projected to reach USD 7.28 billion by 2030, growing at a CAGR of 7.72%. North America dominated the diabetic neuropathy treatment market with a revenue share of 37.67% in 2023. Another report estimates the global diabetic neuropathy treatment market size at USD 4.71 billion in 2024, growing to USD 5.07 billion in 2025, and projected to reach around USD 9.93 billion by 2034, expanding at a CAGR of 7.75% between 2025 and 2034. * Appliance Recycling Services: null * Cellular Transceiver Modules and Associated Wireless Services: null

Here are 3-5 expected drivers of future revenue growth for AI Financial (AIFC) over the next 2-3 years:

1. Growth in blockchain-powered financial technologies and digital asset services: AI Financial Corporation's primary focus is on providing blockchain-powered payment, trading, and settlement infrastructure for digital assets. Future revenue growth is expected from increased adoption of its platforms, such as ALT 5 Prime for digital asset trading and ALT 5 Pay for crypto-currency payments, leading to higher transaction volumes and an expanded institutional and enterprise client base. The company's infrastructure has already processed over $8 billion in cumulative transaction volume since its inception.
2. Expansion into AI-driven financial solutions and tokenization: The company has stated its strategic evolution towards "AI-driven infrastructure" and evaluating "opportunities at the intersection of payments, tokenization, and AI". This strategic direction suggests new product development, enhanced service offerings, and potential market entry into areas leveraging artificial intelligence and tokenization for more programmable and automated financial activities, thereby opening new revenue streams.
3. Advancement and commercialization within the Biotechnology segment: AI Financial Corporation continues to operate a Biotechnology segment. While the company's recent strategic announcements highlight its fintech focus, ongoing development and potential commercialization of novel, non-opioid, and non-addictive therapies, like its lead product candidate JAN101 (which targets poor blood flow in patients with diabetes or peripheral artery disease to treat pain), could contribute to future revenue growth, building upon the company's historical foundation in biopharmaceuticals.

null